Can hereditary hemorrhagic telangiectasia (HHT) cause ankle deep vein thrombosis (DVT)?

HHT Does Not Directly Cause DVT, But Patients Have Significantly Increased Thrombotic Risk

HHT itself does not cause ankle DVT through a direct pathophysiologic mechanism, but patients with HHT have a substantially elevated risk of venous thromboembolism (VTE) including DVT—approximately 2-4 times higher than the general population. The ankle DVT should be evaluated and managed as a standard thrombotic event, but with critical awareness of the patient's concurrent bleeding risk.

Understanding the Paradox: A Bleeding Disorder with Thrombotic Risk

HHT is fundamentally a vascular malformation disorder characterized by telangiectasias and arteriovenous malformations (AVMs) that cause bleeding 1. However, emerging evidence demonstrates a paradoxical increased thrombotic tendency:

• Prospective data shows VTE incidence of 23.1 per 1,000 patient-years in HHT patients overall, rising to 45.1 per 1,000 patient-years in those over 65 years old 2—substantially higher than the general population rate of approximately 1-2 per 1,000 patient-years
• A recent study found 41.7% of HHT patients experienced thrombotic events 3
• Multiple case reports document concurrent DVT and pulmonary embolism in HHT patients 4, 5, 6

Proposed Mechanisms for Increased Thrombosis

While the exact pathophysiology remains incompletely understood, several factors likely contribute:

Vascular dysfunction markers:

• Significantly elevated von Willebrand factor (vWF) activity in HHT patients (149% vs 91% in controls, p<0.001) 3
• Higher vWF antigen levels in patients with AVMs (165% vs 131%, p=0.021) 3
• Elevated stromal cell-derived factor-1 (SDF-1) in non-AVM patients 3

Clinical risk factors:

• Increased schistocytes (3.5% vs 0%, p=0.002) in HHT patients with thrombosis 3
• Elevated ferritin and LDH suggesting chronic hemolysis and endothelial dysfunction 3
• Immobilization from bleeding complications
• Underutilization of thromboprophylaxis during hospitalizations 2—a critical modifiable risk factor

Clinical Approach to DVT in HHT Patients

Immediate Assessment

Evaluate the DVT as you would in any patient, but simultaneously assess:

1. Bleeding risk stratification:

   • Active epistaxis frequency and severity
   • History of gastrointestinal bleeding from telangiectasias
   • Presence and location of known AVMs (pulmonary, hepatic, cerebral)
   • Recent hemoglobin trends and transfusion requirements

2. Provoked vs unprovoked DVT:

   • In the prospective study, 11 of 15 VTE events had identifiable provoking factors 2
   • Four events occurred during hospitalization without thromboprophylaxis 2

Anticoagulation Decision-Making

The current HHT guidelines do not specifically address anticoagulation for VTE 1, leaving clinicians to balance competing risks. Based on available evidence:

Anticoagulation CAN be used in HHT patients with appropriate monitoring:

• Multiple case reports demonstrate successful anticoagulation without catastrophic bleeding 5, 6, 7
• One patient completed 6 months of therapeutic anticoagulation plus 1 year of lower-dose secondary prevention 7
• Rivaroxaban has been used successfully in cerebral venous thrombosis with HHT 5

However, discontinuation rates are substantial:

• 23% discontinuation rate for antiplatelet therapy 3
• 33% discontinuation rate for anticoagulant therapy 3
• Bleeding complications (GI bleeding from angioectasias) do occur 7

Practical Management Algorithm

For acute DVT in HHT:

1. If life-threatening VTE (massive PE, extensive proximal DVT): Anticoagulate with close monitoring—mortality risk outweighs bleeding risk

2. If provoked DVT with removable risk factor:

   • Anticoagulate for standard 3-6 months
   • Consider shorter duration (3 months) given bleeding risk
   • Monitor hemoglobin weekly initially, then monthly

3. If unprovoked DVT:

   • Standard 3-6 months therapeutic anticoagulation
   • Reassess bleeding events during treatment
   • Extended prophylaxis is controversial—individualize based on bleeding severity during initial treatment

4. Agent selection:

   • DOACs (rivaroxaban, apixaban) may be preferred over warfarin for easier reversal and potentially lower GI bleeding risk
   • No head-to-head data in HHT patients 7

Critical Monitoring

• Weekly hemoglobin checks for first month, then monthly
• Establish baseline epistaxis frequency before anticoagulation
• Have low threshold for endoscopy if GI symptoms develop
• Ensure iron supplementation is optimized (common in HHT regardless) 1

Key Pitfall to Avoid

The most critical error is failing to provide thromboprophylaxis during hospitalizations in HHT patients 2. Despite bleeding concerns, the data shows:

• Four VTE events occurred during hospitalization without prophylaxis 2
• The thrombotic risk during acute illness may exceed bleeding risk
• Mechanical prophylaxis should be standard; pharmacologic prophylaxis should be strongly considered unless active bleeding

Bottom Line

The ankle DVT is not caused by HHT's vascular malformations directly, but HHT patients have a 2-4 fold increased VTE risk through endothelial dysfunction and other mechanisms. Treat the DVT with anticoagulation using standard protocols, but with enhanced bleeding surveillance and potentially shorter treatment duration. The bleeding risk is real but manageable in most cases, and withholding anticoagulation for standard indications carries significant mortality risk 2, 3, 7.